The Effectiveness of IL-12 Administration and Fusion on Tumor Antigen Sensitization Methods for Dendritic Cells Derived from Patients with Myelogenous Leukemia.
- Author:
Kee Won KIM
1
;
Suk Young PARK
;
Young Seon HONG
Author Information
- Publication Type:Original Article
- Keywords: Dendritic cells; leukemia; immunotherapy; cell fusion
- MeSH: Antigens, Neoplasm; CD40 Ligand; Cell Fusion; Dendritic Cells*; Humans; Immunotherapy; Interleukin-12*; Leukemia; Leukemia, Myeloid*; Vaccination
- From:Immune Network 2004;4(1):38-43
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: Immunotherapy using dendritic cells (DC) loaded with tumor antigens may represent a potentially effective method for inducing antitumor immunity. We evaluated the effectiveness of DC-based antitumor immune response in various conditions. METHODS: DC were cultured from peripheral blood mononuclear cells (PBMNC) in myelogenous leukemia (ML) and lysates of autologous leukemic cells are used as tumor antigen. The effectiveness of interleukin-12 (IL-12) and CD40L (CD154) on the antigen presenting function of lysates-loaded DC was analyzed by proliferation, cytokine production, and cytotoxicity tests with activated PBMNC (mainly lymphocytes). For generating antigen-loaded DC, direct fusion of DC with ML was studied. RESULTS: Antigen loaded DC induced significantly effective antitumor immune response against autologous leukemic cells. Administration of IL-12 on the DC based antitumor immune response showed higher proliferation activity, IFN-gamma production, and cytotoxic activity of PBMNC. Also, fused cell has a potent antitumor immune response. CONCLUSION: We conclude that lysates-loaded DC with IL-12 may be effectively utilized as inducer of antitumor immune reaction in ML and in vivo application with DC-based antitumor immunotherapy or tumor vaccination seems to be feasible.
